Diflunisal-13C6

Diflunisal-13C6 (MK-647-13C6) is 13C labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

Product Specifications

Product Name Alternative

MK-647-13C6

UNSPSC

12352005

Target

COX; Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C([13C]1=[13C](O)[13CH]=[13CH][13C](C2=CC=C(C=C2F)F)=[13CH]1)O

Molecular Formula

C7 13C6H8F2O3

Molecular Weight

256.15

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Lin JH, et al. Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther. 1985 Nov;235 (2) :402-6.|[3]Winter CA, et al. Analgesic activity of diflunisal [MK-647; 5- (2,4-difluorophenyl) salicylic acid] in rats with hyperalgesia induced by Freund's adjuvant. J Pharmacol Exp Ther. 1979 Dec;211 (3) :678-85.|[4]Cappon GD, et al. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68 (1) :47-56.